

1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| LifeX Fund II US, a series of Life Extension Ventures II | July 2026 | $175M | $27M | 25 |
| LEVC Fund I - US, a series of Life Extension Ventures | August 2022 | $86M | $86M | 100 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Amol Sarva | Quiet | Consumer apps & internet, Digital health, E-commerce & marketplaces | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of LifeX Ventures’s own portfolio companies, based on 5 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of LifeX Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Lux Capital | 1 | Halo Neuro |
| RRE Ventures | 1 | PEEK |
A shared board seat: a company where filings name a LifeX Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.